Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 11/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227360 | 0.93 | DGAT1 (0.47) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL15001246 | 0.93 | DGAT1 (0.47) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL155003 | 0.93 | DGAT1 (0.47) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL3508922 | 0.84 | DGAT1 (0.44) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL15001186 | 0.78 | DGAT1 (0.48) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL16272832 | 0.78 | DGAT1 (0.48) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL18674117 | 0.77 | DGAT1 (0.44) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL15001205 | 0.77 | DGAT1 (0.44) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL29744208 | 0.76 | DGAT1 (0.46) | DGAT1USP30LPLLIPGFFAR1 | |
| SCHEMBL1059779 | 0.76 | DGAT1 (0.49) | DGAT1USP30LPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130142873-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142873-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | CYP11B2, CYP27A1, CYP11B1 | DGAT1 3081/4885USP30 4398/4885LPL 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.